Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-Cell lymphomas (LBCL) - Abramson, S; Palomba, ML; Gordon, LI (Blood, 2021)
et al.